Imugene Limited 2024 Cancer Therapeutics Investor Presentation

Imugene Limited presents its cancer drug pipeline with 4 therapeutics in clinical trials backed by expert leadership with 13 prior FDA-approved cancer drugs. The company highlights a strong A$114.1M cash position, A$432M market capitalisation, and long-life patent portfolio with key catalysts expected in 2024.